Drug intelligence / Profile preview

ABC015

Development stage: Preclinical
Lead developer: Abcuro
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

ABC015 is a preclinical anti–killer cell lectin-like receptor subfamily G member 1 (KLRG1) blocking monoclonal antibody being developed by Abcuro as an oncology immunotherapy. By neutralizing the inhibitory receptor KLRG1 on highly differentiated cytotoxic T cells and natural killer (NK) cells, ABC015 is designed to selectively restore effector function of these cells within the tumor microenvironment, thereby enhancing antitumor activity while sparing less-differentiated lymphocyte subsets. The program is supported by the Multiple Myeloma Research Foundation and is being explored particularly in multiple myeloma and other cancers where KLRG1-expressing cytotoxic lymphocytes are functionally suppressed.[2][5]

Targets

MAFA (V-maf musculoaponeurotic fibrosarcoma oncogene homolog A)

Beyond the preview

Go deeper on ABC015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABC015.

Explore the full profile